Company: TYRA
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0000950170-25-046124
Chunk: 180

Company: Tyra Biosciences, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1B
Chunk 180
---
uance of pre-funded warrants, under    Private Placement, net of issuance    costs of $0.2 million

    —

    —

    79,022

    —

    —

    79,022

    Issuance of common stock pursuant to    pre-funded warrant exercise

    705,000

    —

    —

    —

    —

    —

    Exchange of common stock for    pre-funded warrants

    (3,000,000
    )

    —

    —

    —

    —

    —

    Issuance of common stock under   benefit plans

    664,184

    —

    2,557

    —

    —

    2,557

    Vesting of shares of common   stock subject to repurchase

    70,104

    —

    43

    —

    —

    43

    Stock-based compensation

    —

    —

    22,801

    —

    —

    22,801

    Unrealized gain on marketable    securities available-for-sale, net

    —

    —

    —

    389

    —

    389

    Net loss

    —

    —

    —

    —

    (86,481
    )

    (86,481
    )

    Balance at December 31, 2024

    50,749,945

    $
    5

    $
    593,687

    $
    770

    $
    (251,311
    )
     
    $
    343,151

See accompanying notes to financial statements.

118

Tyra Biosciences, Inc.

Statements of Cash Flows

(in thousands)

    Year EndedDecember 31,

    2024

    2023

    Cash flows from operating activities:

    Net loss
     
    $
    (86,481
    )
     
    $
    (69,134
    )

    Adjustments to reconcile net loss to net cash used in operating activities:

    Depreciation

    519

    357

    Stock-based compensation

    22,801

    13,525

    Accretion on marketable securities, net

    (5,884
    )

    (1,247
    )

    Changes in operating assets and liabilities:

    Prepaid expenses and other assets

    (169
    )

    (2,823